Ransomware Tracker by ExposureDrift
Dashboard / Victims / FUJIFILM

FUJIFILM was listed on 05 April 2025 by the sarcoma ransomware group (the group's claim; Ransomware Tracker by ExposureDrift has not confirmed a breach). sarcoma listed 14 organizations that month and 144 in total.

  • Listed 593 days ago.
  • 536 organizations were listed by all groups in April 2025, see the month.
  • 78 in Technology that month.
  • 6 in JP that month.
  • 2 other listings for the same organization.

Updated 2026-11-19 06:11 UTC. Data: public leak-site listings. How we work.

FUJIFILM corporate emblem
Listed by sarcoma Disclosed: 2025-04-05 08:45 UTC

FUJIFILM

fujifilm.com Technology JP

Named in 3 separate listings

Other listings name this organization: a different group, or the same group months apart. Each is a claim the group published, not a confirmed breach. The same group listing it again within a few months is not counted: that is the same listing sent twice or moved from countdown to published.

This listing: sarcoma, 05 Apr 2025 shinyhunters, 03 Oct 2025 revil, 01 Jun 2021

Threat Group Post & Evidence

Listed by
Sarcoma 144 listings in total

The listing states no data size and no ransom demand.

No capture of the original post

We only show a screenshot when we captured the group's own page ourselves. For this listing we have not, so none is shown.

What the group says it holds

Taken from the group's own post. Ransomware Tracker by ExposureDrift has not seen the data and cannot confirm any of this.

Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing f…
Show the full post (1066 characters)

Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing facility for producing investigational and commercial drugs through its subsidiary, FUJIFILM Toyama.Geo: Singapore - Leak size: NO DATA 1 pdf - Contains: NO DATA 1 pdf

Amounts as written

  • 1 pdf

Plain-English summary AI-written

The group says it holds information about Fujifilm’s liposome research and development, including clinical trials and preclinical studies.

Written by an AI model (openai/gpt-6-luna) from the post above. It can contain mistakes: rely on the quote, not the summary.

What to do about this listing

Choose who you are. Each step shows why it appears and, where we have one, its source. General guidance, not legal or incident-response advice.

If you work with FUJIFILM (customer, supplier or partner)

Within 3 days

  • Do not open the group's page or download the data Do not visit the leak site or download files from a listing. Holding stolen data can be unlawful, and the files can carry malware. Wait for the company's own notice. Why: A safety rule for any leak listing.
  • Ask FUJIFILM directly Write to your contact and ask whether your data, or your access to their systems, is in scope, and ask for a written statement. Your contract or data-protection law may oblige them to tell you if your data is affected: check the notification clause. Why: A listing is only the group's claim; the company is the one who can confirm what was taken.
  • Review what FUJIFILM can reach of yours List the accounts, API keys, VPN or SSO connections and shared mailboxes this company has with you. Rotate the keys you gave them and remove access they do not need. Why: Access a supplier holds is how a listing about them can become a problem for you.

Within 30 days

  • Keep watching FUJIFILM A supplier's listing can change after the first sighting: the group can add data, change the status or publish. Add the company to your supplier list to be told, and check your own domain too. Why: A listing is a moving claim, not a single event. Add to your supplier list Check your own domain
If you are FUJIFILM

Within 3 days

  • Find out what was actually taken The post names no specific kind of data, so no data-specific steps are shown. Check the group's own post and your logs to learn what is claimed and what is real. Why: The listing text names no data types.
  • Size the exposure against your own systems Inventory which systems hold data of the kind and volume claimed, so notification and legal decisions rest on your records rather than the group's figures. Why: The post claims: 1 pdf. Treat group figures as unverified.
  • Lock down exposed admin, VPN and SSO panels Restrict by IP allow-list or a zero-trust proxy and require MFA. Why: A passive scan found 2 critical panel(s) reachable from the internet.
  • Remove dangling DNS records Delete or re-point records that allow subdomain takeover. Why: A passive scan found 1 dangling subdomain(s).
  • Retire staging and dev exposure Take non-production hosts off the internet or behind authentication, and rotate any secrets they held. Why: A passive scan found 1 non-production host(s) that are public.
  • Check regulatory and stakeholder notification duties Japan: the APPI requires reporting certain leaks to the Personal Information Protection Commission and notifying affected people. This is general guidance, not legal advice: confirm current rules with counsel. Why: Listing country: Japan.
General readiness for any ransomware claim (not about this listing)
  • Offline, immutable backups and a restore drill Keep backups outside domain-admin reach and practise a restore; a leak does not remove the risk of re-encryption. Why: General practice for any ransomware claim; not specific to this listing.
  • Look for mass file access and unusual outbound transfers Review EDR, proxy and identity logs for bulk reads, archive creation and large uploads to file-sharing services. Why: General practice for any ransomware claim; not specific to this listing.
  • Phishing-resistant MFA on remote access Enforce MFA on VPN, SSO and admin panels, and retire password-only or SMS-based remote access. Why: General practice for any ransomware claim; not specific to this listing.

Listing details

Resolved Domain fujifilm.com
Industry Vertical Technology
Country JP
Enrichment Status ENRICHED

Listing severity score (heuristic)

50/100 • GUARDED

A heuristic built from sector, group, data volume and claim details. It is not evidence that a breach occurred or a measure of harm.

1. Sector Criticality 20/30 pts
Technology and communications
2. Group tier 10/25 pts
Tier 3: all other groups
3. Data Volume & PII Scope 10/25 pts
Baseline: no size or sensitive data named in the post
Formula: sector • group tier • data claimed (scaled to 100) Rule-based score

External Attack Surface Profile

ASM Intelligence
100/100 • CRITICAL
Last Audited: 2026-11-14 17:28 UTC Passive Recon
Total Network Assets 29
9 hosts • 20 unique IPs
0 cloud-hosted • 10 SaaS
Subdomain Assets 9
Critical Panels 2 (VPN/Admin/SSO)
Non-Prod / UAT 1 Staging/Dev
SaaS Ecosystem 10 Cloud Apps
Primary CSP Public Cloud / E
Email Security Grade A+ (SPF/DMARC)
Open the full attack surface scan →
Is Your Organization Exposed?

Run a free passive scan on your own domain to see what an attacker can see from the outside.

Defense Telemetry

Passive DNS
Mail Gateway Proofpoint Enterprise Protection
DNS Authority Authoritative DNS (jp)
Edge CDN / Shield None
SPF Record Configured
DMARC Policy Enforced
Public DNS records only • no port scanning

More Claims by sarcoma

All →
Ivan Smith Furniture
Retail & E-Commerce 2026-10-31 10:31 UTC
Don Pickett & Associates
Professional Services 2026-10-23 11:48 UTC
victim
Unknown 2026-10-13 15:38 UTC
GYF
Technology 2026-03-30 09:25 UTC
Propane Levac Inc.
Energy & Utilities 2026-01-23 09:58 UTC
MecMatica
Technology 2026-01-20 07:33 UTC

Other listings for this name

3 listings
sarcoma Viewing Now
2025-04-05 08:45 UTC Severity: 50/100
2025-10-03 15:45 UTC Open listing →
revil ELEVATED
2021-06-01 00:00 UTC Open listing →